A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Previous uncontrolled clinical trials have shown the in vivo retrovirus (RV)-mediated transduction of glioblastoma cells with the herpes simplex virus thymidine kinase (HSV-tk) gene and subsequent systemic treatment with ganciclovir to be feasible and well tolerated. However, because of continued tumor progression in most patients, the antitumor effect could not be determined using historical controls. Here, we describe a phase III, multicenter, randomized, open-label, parallel-group, controlled trial of the technique in the treatment of 248 patients with newly diagnosed, previously untreated glioblastoma multiforme (GBM). Patients received, in equal numbers, either standard therapy (surgical resection and radiotherapy) or standard therapy plus adjuvant gene therapy during surgery. Progression-free median survival in the gene therapy group was 180 days compared with 183 days in control subjects. Median survival was 365 versus 354 days, and 12-month survival rates were 50 versus 55% in the gene therapy and control groups, respectively. These differences were not significant. Therefore, the adjuvant treatment improved neither time to tumor progression nor overall survival time, although the feasibility and good biosafety profile of this gene therapy strategy were further supported. The failure of this specific protocol may be due mainly to the presumably poor rate of delivery of the HSV-tk gene to tumor cells. In addition, the current mode of manual injection of vector-producing cells with a nonmigratory fibroblast phenotype limits the distribution of these cells and the released replication-deficient RV vectors to the immediate vicinity of the needle track. Further evaluation of the RV-mediated gene therapy strategy must incorporate refinements such as improved delivery of vectors and transgenes to the tumor cells, noninvasive in vivo assessment of transduction rates, and improved delivery of the prodrug across the blood-brain and blood-tumor barrier to the transduced tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Moolten, F. L. (1986) · PubMed · Cited by 972
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., & Oldfield, E. H. (1993) · PubMed · Cited by 433
Huber, B. E., Austin, E. A., Richards, C. A., Davis, S. T., & Good, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8302 · Cited by 420
Li Bi, W., Parysek, L. M., Warnick, R., & Stambrook, P. J. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-725 · Cited by 416
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., & Oldfield, E. H. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.82.6.1021 · Cited by 341
Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Barba, D., Hardin, J., Sadelain, M., & Gage, F. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4348 · Cited by 297
Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.-L., Philippon, J., & Glioblastoma, S. G. O. G. T. F. (1998) · Human Gene Therapy · doi:10.1089/10430349850019436 · Cited by 269
Shand, N., Weber, F., Mariani, L., Bernstein, M., Gianella-Borradori, A., Long, Z., Sorensen, A. G., & Barbier, N. (1999) · Human Gene Therapy · doi:10.1089/10430349950016979 · Cited by 247
Ezzedine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B. R., & Breakefield, X. O. (1991) · PubMed · Cited by 239
Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study
Brandes, A. A., Scelzi, E., Salmistraro, G., Ermani, M., Carollo, C., Berti, F., Zampieri, P., Baiocchi, C., & Fiorentino, M. V. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00167-6 · Cited by 206
Vile, R. G., Castleden, S., Marshall, J. F., Camplejohn, R. S., Upton, C., & Chong, H. (1997) · International Journal of Cancer · Cited by 205
Herrlinger, U., Woiciechowski, C., Sena‐Esteves, M., Aboody, K. S., Jacobs, A. H., Rainov, N. G., Snyder, E. Y., & Breakefield, X. O. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0046 · Cited by 152
Self-citationThe basis for current treatment recommendations for malignant gliomas
Fine, H. A. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01052722 · Cited by 129
Palù, G., Cavaggioni, A., Calvi, P., Franchin, E., Pizzato, M., Boschetto, R., Parolin, C., Chilosi, M., Ferrini, S., Zanusso, A., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300805 · Cited by 128
Ishii-Morita, H., Agbaria, R., Mullen, C., Hirano, H., Koeplin, D., Ram, Z., Oldfield, E. H., Johns, D., & Blaese, R. M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300379 · Cited by 126
Harsh, G. R., Deisboeck, T. S., Louis, D. N., Hilton, J., Colvin, M., Silver, J. S., Qureshi, N. H., Kracher, J., Finkelstein, D., Chiocca, E. A., et al. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.92.5.0804 · Cited by 107
Molecular changes during the genesis of human gliomas
Sehgal, A. (1998) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199801/02)14:1<88::aid-ssu11>3.0.co;2-5 · Cited by 92
Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy.
Blasberg, R. G., & Tjuvajev, J. G. (1999) · PubMed · Cited by 83
Packer, R. J., Raffel, C., Villablanca, J. G., Tonn, J.-C., Burdach, S. E., Burger, K., LaFond, D., McComb, J. G., Cogen, P. H., Vezina, G., et al. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.92.2.0249 · Cited by 82
Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
DiMeco, F., Rhines, L. D., Hanes, J. S., Tyler, B., Brat, D. J., TORCHIANA, E., Guarnieri, M., Colombo, M. P., Pardoll, D. M., Finocchiaro, G., et al. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.3.0419 · Cited by 64
Long, Z., Lie-ping, L., Grooms, T., Lockey, C., Nader, K., Mychkovsky, I., Mueller, S. N., Burimski, I., Ryan, P. C., Kikuchi, G. E., et al. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.8-1165 · Cited by 57
Enhanced expression of thymidine kinase in human cells following ionizing radiation
Boothman, D. A., Davis, T. W., & Sahijdak, W. M. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90019-1 · Cited by 56
Biology and treatment of malignant glioma.
Shapiro, W. R., & Shapiro, J. R. (1998) · PubMed · Cited by 56
Rainov, N. G., Kramm, C. M., Aboody-Guterman, K. S., Chase, M., Ueki, K., Louis, D. N., Harsh, G. R., Chiocca, A., & Breakefield, X. O. (1996) · PubMed · Cited by 47
Self-citationMolecular Biology and Neurosurgery in the Third Millennium
Rutka, J. T., Taylor, M. D., Mainprize, T. G., Langlois, A., Ivanchuk, S. M., Mondal, S., & Dirks, P. B. (2000) · Neurosurgery · doi:10.1097/00006123-200005000-00002 · Cited by 42
Mullen, C. A., Anderson, L. D., Woods, K. V., Nishino, M., & Petropoulos, D. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.14-2019 · Cited by 41
Long, Z., Lu, P., Grooms, T., Mychkovsky, I., Westley, T., Fitzgerald, T., Sharma-Chibber, S., Shand, N., Mcgarrity, G., & Otto, E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018490 · Cited by 40
LeMay, D. R., Kittaka, M., Gordon, E. M., Gray, B., Stins, M. F., McComb, J. G., Jovanovic, S. S., Tabrizi, P., Weiss, M. H., Bartus, R. T., et al. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.7-989 · Cited by 34
Kramer, E. D., Packer, R. J., Ginsberg, J. P., Goldman, S., Thompson, S. J., Bayer, L. A., Shen, V., Harris, R., Khan, S. P., & Finlay, J. L. (2008) · Pediatric Neurosurgery · doi:10.1159/000121259 · Cited by 26
Cited by
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Primary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Metadata
- Authors
- Rainov, N. G.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2000-11-20
- Volume
- 11
- Issue
- 17
- Pages
- 2389-2401
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2172477250
- Cited by
- 698
- References
- 34
- FWCI
- 18.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.